Aurobindo Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Aurobindo Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1436.1, up 1.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.75% on the day, quoting at 24195.15. The Sensex is at 77763.49, down 0.96%. Aurobindo Pharma Ltd has risen around 12.06% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 13.11 lakh shares today, compared to the daily average of 17.53 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 1436.1, up 1.33% on the day. Aurobindo Pharma Ltd is up 14.18% in last one year as compared to a 0.21% drop in NIFTY and a 4.48% drop in the Nifty Pharma index.

The PE of the stock is 38.5 based on TTM earnings ending December 25.

The product is indicated for the temporary relief of cough caused by minor throat and bronchial irritation, such as that associated with the common cold or inhaled irritants. It also helps suppress the urge to cough, aiding sleep.

The approved formulation is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Delsym extended-release oral suspension, 30 mg/5 mL, marketed by RB Health (US) LLC.

Aurobindo Pharma said the product will be manufactured at Unit IV of APL Healthcare, its wholly owned subsidiary, and is expected to be launched in Q2 FY27.

According to Nielsen data for the 12 months ended February 2026, the product has an estimated market size of $138 million. With this approval, the company now has a total of 580 ANDA approvals from the USFDA, including 557 final approvals and 23 tentative approvals.

The official announcement was made on 17 April 2026, after market hours.

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 7.6% rise in consolidated net profit to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

The counter shed 0.62% to Rs 1,377 on the BSE.

The approved product is bioequivalent and therapeutically equivalent to the reference-listed drug, Ravicti, marketed by Horizon Therapeutics U.S. Holding LLC.

The company said the product will be manufactured at its Unit-III facility and will be launched immediately.

According to IQVIA MAT data, the approved drug has an estimated market size of $50.2 million for the 12 months ending February 2026. With this approval, Aurobindo Pharma?s total ANDA approvals from the USFDA stand at 579, including 556 final approvals and 23 tentative approvals.

Glycerol phenylbutyrate oral liquid is indicated as a nitrogen-binding agent for the chronic management of patients with urea cycle disorders (UCDs) who cannot be adequately managed through dietary protein restriction and amino acid supplementation alone.

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 7.6% rise in consolidated net profit to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

The counter rose 0.09% to Rs 1,387.30 on the BSE.

Aurobindo Pharma announced the receipt of the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Ravicti Oral Liquid 1.1 grams per mL, of Horizon Therapeutics U.S. Holding LLC.

The product will be manufactured by Unit-III of the Company and will be launched immediately.

The approved product has an estimated market size of US$ 50.2 million for the twelve months ending February 2026, according to IQVIA MAT. Aurobindo Pharma now has a total of 579 ANDA approvals (556 final approvals and 23 tentative approvals) from USFDA.

Glycerol Phenylbutyrate Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.